10-K: EBR Systems Files 10-K, Anticipates U.S. Market Launch in 2025 Pending FDA Approval

EBR Systems files its 10-K report, highlighting progress towards potential U.S. commercial launch of the WiSE CRT System in 2025, contingent on FDA approval.

Summary

• EBR Systems, a medical device company, is developing the WiSE CRT System, a leadless cardiac pacing technology.
• The company submitted the final module of its PMA submission to the FDA on August 28, 2024.
• Subject to FDA approval, EBR Systems anticipates a commercial launch of the WiSE CRT System in the U.S. in 2025.
• The company plans a phased Limited Market Release (LMR) strategy in the U.S., focusing on high-volume sites.
• The expected average selling price (ASP) in the U.S. is approximately $45,000 per WiSE CRT system.
• OUS commercial activities will commence after regulatory approvals and certification in target markets like Australia, the United Kingdom, and the European Union.
• The company's intellectual property portfolio includes 63 granted U.S. patents and 55 granted non-U.S. patents.
• As of December 31, 2024, the company had 89 full-time employees.
• The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant was approximately $ 143 million as of June 30, 2024.
• As of March 15, 2025, the registrant had 372,851,324 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's progress towards a potential product launch and positive clinical trial results, the company's history of net losses and dependence on future funding create uncertainty.

Positives

• The WiSE CRT System has a Breakthrough Device Designation from the FDA, which provides greater access to the FDA during the premarket review phase, a prioritized review process, and potentially up to three years of favorable reimbursement coverage in the U.S. following such approval.
• The SOLVE-CRT study met its primary 6-month efficacy endpoint with a 16.4% reduction in mean LVESV, significantly favorable to the 9.3% performance goal.
• The SOLVE-CRT study met its primary 6-month safety endpoint with an 80.9% rate of freedom from deviceor procedure-related complications, significantly favorable to the 70% performance goal.
• The company believes the WiSE CRT System is 95% smaller by volume compared to commercially available leadless pacemakers.
• The FDA completed the manufacturing site Pre-Approval Inspection (PAI) with no Form FDA 483 observations.

Negatives

• The company has a history of net losses and expects to continue to incur losses for at least the next several years.
• The company has limited sales and marketing resources.
• The company has limited experience manufacturing its products in commercial quantities.
• The company has capitalized pre-launch inventories prior to receiving FDA approval, which could require a write-off if approval or market acceptance is delayed or does not occur.
• The company's existing indebtedness contains restrictions that limit its flexibility in operating its business.

Risks

• The company's business is dependent on obtaining regulatory approval and commercializing its WiSE CRT technology, which is still under development.
• Coverage and adequate reimbursement may not be available for the company's products or the procedures that utilize its products.
• The company depends upon third-party suppliers, including single-source suppliers, making it vulnerable to supply disruptions and price fluctuations.
• The commercial success of the company's products will depend upon attaining significant market acceptance among hospitals, physicians, patients, and payors.
• The company may be subject to product liability claims if its products cause, or merely appear to have caused, an injury or death.
• The company may not be able to achieve or maintain satisfactory pricing and margins for its products.
• The company may not realize the benefits from continued research and development costs.
• The company may not be able to achieve or maintain satisfactory pricing and margins for its products.
• The company's customers may not be able to achieve adequate reimbursement for using its products in the United States or in key foreign jurisdictions.
• The company's ability to utilize its net operating loss carryforwards may be limited.
• The company is subject to stringent privacy laws, rules, regulations, information security and privacy policies, contractual obligations, and other obligations governing the use, processing and cross-border transfer of personal information.
• The company may be subject to securities litigation, which is expensive and could divert management attention.
• The company may face difficulties encountered by many medical technology companies early in their commercialization.
• The company is dependent on the protection and enforcement of its intellectual property rights.
• The company may be subject to future third party intellectual property rights disputes.
• The market price of the company's CDIs and common stock may be volatile, which could cause the value of its common stock to decline.
• The requirements of being an SEC registrant may strain the company's resources, divert management's attention and affect its ability to attract and retain qualified Board of Directors members.
• The different characteristics of the capital markets in Australia and the United States may negatively affect the trading prices of the company's CDIs and common stock and may limit its ability to take certain actions typically performed by a U.S. company.

Future Outlook

Subject to FDA review and approval, and pre-commercial activities, the company expects to commercially launch the WiSE CRT System in the U.S. in 2025.

Industry Context

The document discusses the competitive landscape, noting that leadless devices are expected to play an increasingly important role in the future pacemaker market and that the WiSE CRT System is the only device able to upgrade patients with leadless pacemakers to CRT.

Comparison to Industry Standards

• The WiSE CRT System is the only device able to upgrade patients with Medtronic's Micra or Abbotts Aveir to CRT.
• The WiSE CRT System is the only therapy demonstrated in clinical study that can deliver LVEP and potentially broaden the spectrum of patients who could benefit from CRT.
• The leadless pacemakers currently on the market are for bradycardia indication, it is anticipated that the entry of Abbotts Aveir DR dual chamber device could further increase the adoption of leadless pacemakers.

Related Party Transactions

• Host-Plus, a beneficial owner of more than 5% of the company's common stock, participated in the institutional placement and purchased 7,868,138 CDIs for the aggregate purchase price of $4,403,403.

Stakeholder Impact

• Shareholders: Dilution may occur from future equity offerings.
• Employees: Job security and potential for growth depend on the company's success.
• Customers: Access to a new treatment option for heart failure depends on FDA approval and market adoption.
• Suppliers: Continued business depends on the company's financial stability and production needs.
• Creditors: Repayment of debt depends on the company's ability to generate revenue and manage cash flow.

Next Steps

• The company will continue to work with the FDA to obtain approval for the WiSE CRT System.
• The company will implement its phased Limited Market Release (LMR) strategy in the U.S.
• The company will pursue regulatory approvals and certification in target OUS markets.
• The company will continue research and development activities to improve the use and performance of the WiSE CRT System.

Key Dates

Keywords

WiSE CRT System, cardiac resynchronization therapy, leadless pacing, FDA approval, medical device, SOLVE-CRT, commercial launch, intellectual property, regulatory approval, EBR Systems